Sulprostone


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IV Cervical dilatation in the 1st trimester 500 mcg via infusion. Termination of pregnancy in the 2nd trimester Infuse at 100 mcg/hr for up to 10 hr; may increase rate up to 500 mcg/hr. Max total: 1.5 mg. May repeat once 12-24 hr later if needed. Postpartum haemorrhage Initial: Infuse at 100 mcg/hr, up to 500 mcg/hr if needed. Maintenance: 100 mcg/hr. Total dose: Up to 1.5 mg in 24 hr.
Dosage Details
Intravenous
Cervical dilatation in the 1st trimester
Adult: 500 mcg infusion over 3-6 hr.

Intravenous
Pregnancy termination in the 2nd trimester
Adult: 100 mcg/hr infusion for up to 10 hrs; if necessary, increase infusion rate up to 500 mcg/hr to a max total dose of 1.5 mg. May be repeated once 12-24 hrs later if unsuccessful.

Intravenous
Postpartum haemorrhage
Adult: Initially, 100 mcg/hr via infusion. May increase to 500 mcg/hr if needed to control bleeding, after which reduce to a maintenance dose of 100 mcg/hr. Not to exceed a total dose of 1.5 mg in 24 hr.
Contraindications
Pelvic infection; history of pelvic inflammatory disease. Active cardiac, pulmonary, renal or hepatic disease. Smokers or those who have smoked in the last 2 yr.
Special Precautions
Glaucoma or raised intraocular pressure, pre-existing or history of asthma, pre-existing or history of epilepsy, hepatic or renal dysfunction, CV disease.
Adverse Reactions
Bronchoconstriction, nausea, vomiting, diarrhoea, abdominal pain, back pain, rash, flushing,shivering, headache, dizziness, hypotension, hypertension, hypersensitivity reactions, convulsions, EEG changes, local tissue irritation, erythema, pyrexia, raised WBC.
Potentially Fatal: Sudden CV collapse, uterine rupture
Drug Interactions
Concurrent use potentiates effect of oxytocin.
Action
Description: Sulprostone, a synthetic derivative of dinoprostone (prostaglandin E2), is a selective agonist for EP3 receptors.
Disclaimer: This information is independently developed by MIMS based on Sulprostone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in